Ocriplasmin Research to Better Inform Treatment (ORBIT)

Trial Profile

Ocriplasmin Research to Better Inform Treatment (ORBIT)

Phase of Trial: Phase IV

Latest Information Update: 11 May 2017

At a glance

  • Drugs Ocriplasmin (Primary)
  • Indications Retinal disorders
  • Focus Therapeutic Use
  • Acronyms ORBIT
  • Sponsors ThromboGenics
  • Most Recent Events

    • 11 May 2017 According to a ThromboGenics media release, data from this trial were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2017 annual meeting
    • 20 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 29 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top